PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin®

Journal of Controlled Release

Volumn 97, Issue 1, 2004, Pages 157-171

  Hosseinkhani, Hossein ^a   Tabata, Yasuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cationization; Enhanced gene expression; PEGylation; Pronectin; Tumor targeting

Indexed keywords

DNA; ESTERS; FLUORESCENCE; GENES; MICROSCOPIC EXAMINATION; NUCLEIC ACID SEQUENCES; POSITIVE IONS;

GENE EXPRESSION; SPERMINE; TUMOR TARGETING;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; ESTER; HYDROXYL GROUP; MACROGOL; PLASMID DNA; PRONECTIN; PRONECTIN F; SPERMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATION TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG TARGETING; FIBROSARCOMA; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; MALE; MOLECULAR SIZE; MOLECULE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TARGET ORGAN; TUMOR; ZETA POTENTIAL;

ANIMALS; DNA; DRUG DELIVERY SYSTEMS; FIBRONECTINS; GENE THERAPY; MICE; OLIGOPEPTIDES; PLASMIDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 2442473962     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.02.025     Document Type: Article

References (81)

1. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12:1995;825-830
2. Lew D., Parker S.E., Latimer T., Abai A.M., Kuwahara-Rundell A., Doh S.G., Yang Z., Laface D., Gromkowski S.H., Nabel G.I., Manthorpe M., Norman J. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum. Gene Ther. 6:1995;553-564
3. Yu L., Suh H., Koh J.J., Kim S.W. Systemic administration of terplex DNA system: pharmacokinetics and gene expression. Pharm. Res. 18(9):2001;1277-1283
4. Kircheis R., Blessing T., Brunner S., Wightman L. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J. Control. Release. 72:2001;165-170
5. Liu F., Huang L. Development of non-viral vectors for systemic gene delivery. J. Control. Release. 78:2002;259-266
6. Liu Y. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15:1997;167-173
7. Li S., Huang L. in vivo gene transfer via intravenous administration of cationic lipid protamine DNA (LPD) complexes. Gene Therapy. 4:1997;891-900
8. Templeton N.S. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15:1997;647-652
9. Senior J. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta. 1062:1991;77-82
10. Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposome and on the target binding of immunoliposomes in vivo. FEBS Lett. 284:1991;263-266
11. Torchilin V.P. Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim. Biophys. Acta. 1195:1994;181-184
12. Woodle M.C., Engbers C.M., Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5:1994;493-496
13. Budker V., Budker T., Zhang G., Subbotin V., Loomis A., Wolff J.A. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J. Gene Med. 2:2000;76-88
14. Stewart M.J., Plautz G., Delbuono L., Yang Z.Y., Xu L., Gao X., Huang L., Nabel E.G., Nabel G.J. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther. 3:1992;267-275
15. Zhu N., Liggitt D., Liu Y., Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science. 261:1993;209-211
16. Liu Y., Mounkes L.C., Liggitt H.D., Brown C.S., Solodin I., Heath T.D., Debs R.J. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15:1997;167-173
17. Goula D., Benoist C., Mantero S., Merlo G., Levi G., Demeneix B.A. Polyethylenimine-based intravenous delivery of transgene to mouse lung. Gene Ther. 5:1998;1291-1295
18. Hofland H.E.J. In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharm. Res. 14:1997;742-749
19. Mahato R.I. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum. Gene Ther. 9:1998;2083-2099
20. Nabel G.J., Nabel E.G., Yang Z.Y., Fox B.A., Plautz G., Gao X., Huang L., Shu S., Gordon D., Chang A.E. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biology activity, and lack of toxicity in humans. Proc. Acad. Sci. U. S. A. 90:1993;11307-11311
21. Egilmez N.K., Yoshimi I., Bankert R.B. Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer. Biochem. Biophys. Res. Commun. 221:1996;169-173
22. Coll J.L., Negoescu A., Louis N., Sachs L., Tenaud C., Girardot V., Demeinex B., Brambilla E., Brambilla C., Favrot M. Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum. Gene Ther. 9:1998;2063-2074
23. Kircheis R. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med. 1:1999;111-120
24. Coll J.L., Chollet P., Brambilla E., Desplanques D., Behr J.P., Favrot M. In vivo delivery of tumors of DNA complexed with linear polyethylenimine. Hum. Gene Ther. 10:1999;1659-1666
25. Wagner E., Curiel D., Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14:1994;113-136
26. Kircheis R., Wightman L., Schreiber A., Robitza B., Rossler V., Kursa M., Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8:2001;28-40
27. Boulikas T. Cancer gene therapy and immunotherapy. Int. J. Oncol. 9:1996;941-954
28. Kong H.L., Crystal R.G. Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst. 90:1998;273-286
29. Pietersz G.A., McKenzie I.F.C. Antibody conjugates for the treatment of cancer. Immunol. Rev. 129:1992;57-80
30. Thorpe P.E., Derbyshire E.J. Targeting the vasculature of solid tumors. J. Control. Release. 129:1997;57-80
31. Kircheis R., Kichler A., Wallner G., Kursa M., Ogris M., Felzmann T., Buchberger M., Wagner E. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4:1997;409-418
32. Kosmas C., Kalofonos H., Epenetos A.A. Monoclonal antibodies. Future potential in cancer chemotherapy. Drugs. 38:1989;645-657
33. Wawrzynczak E.J., Davies A.J. Strategies in antibody therapy of cancer. Clin. Exp. Immunol. 82:1990;189-193
34. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release. 74:2001;47-61
35. Tabata Y., Kawai T., Murakami Y., Ikada Y. Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. Drug Deliv. 4:1997;213-221
36. Luo Y., Prestwich G.D. Cancer-targeted polymeric drugs. Curr. Cancer Drug Targets. 2:2002;209-226
37. Takakura Y., Kitajima M., Matsumoto S., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I: physicochemical characteristics and in vivo antitumor activity. Int. J. Pharm. 37:1987;135-143
38. Takakura Y., Atsumi R., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge: II. Disposition and pharmacokinetics following intravenous and intramuscular adminstration. Int. J. Pharm. 37:1987;145-154
39. Tabata Y., Murakami Y., Ikada Y. Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release. 250:1998;123-133
40. Kopecek J., Kopeckova P., Minko T., Lu Z.R., Peterson C.M. Water soluble polymers in tumor targeted delivery. J. Control. Release. 74:2001;147-158
41. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3:1992;175-210
42. Nomura T., Saikawa A., Morita S., Sakaeda Kakutani T., Yamashita F., Honda K., Takakura Y., Hashida M. J. Control. Release. 52:1998;239-252
43. Imoto H., Sakamura Y., Ohkouchi K., Atsumi R., Takakura Y., Sezaki H., Hashida M. Cancer Res. 52:1992;4396-4401
44. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346
45. Atsumi R., Endo K., Kakutani T., Takakura Y., Hashida M., Sezaki H. Cancer Res. 47:1987;5546-5551
46. Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6:1999;595-605
47. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4:2002;495-499
48. Kaul G., Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 19:2002;1061-1067
49. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 28 Suppl A:2002;13-26
50. Bukowski R.M., Tendler C., Cutler D., Rose E., Laughlin M.M., Statkevich P. Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 95:2002;389-396
51. Pehamberger H. Perspectives of pegylated interferon use in dermatological oncology. Recent Results Cancer Res. 160:2002;158-164
52. Fang J., Sawa T., Akaike T., Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 62:2002;3138-3143
53. Skubitz K.M. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer. Invest. New Drugs. 20:2002;101-104
54. Eng C., Mauer A.M., Fleming G.F., Bertucci D., Rotmensch J., Jacobs R.H., Ratain M.J. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann. Oncol. 12:2001;1743-1747
55. Caplen N.J., Alton E.W., Middleton P.G. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1(1):1995;39-46
56. Cotten M., Wagner E. Non-viral approaches to gene therapy. Curr. Opin. Biotechnol. 4(6):1993;705-710
57. Kabanov A.V., Kabanov V.A. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug. Chem. 6(1):1995;7-20
58. Behr J.P. Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjug. Chem. 5:1994;382-389
59. Ruoslahti E., Pierschbacher M.D. New perspective in cell adhesion: RGD and inergrins. Science. 238:1987;491-497
60. Williams J.A. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the receptors. Path Biol. 40:1992;813-821
61. F.A. Ferrari, C. Richardson, J. Chambers, J. Causey, S.C. Pollock, Construction of synthetic DNA and its use in large polypeptide synthesis, WPO Patent Application no. WO88/03533 (1986).
62. Cappello J., Ferrari F. Microbial production of structural protein polymers. Mobley D.P. Plastic from Microbes. 1994;35-92 Hanser Publication, Munich
63. Pierschbacher M.D., Rouslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 309:1984;30-33
64. Cappello J., Crissman J.W. The design and production of bioactive protein polymers for biomedical application. Polymer Preprints. 31:1990;193
65. Hynes R.O. Integrins: a family of cell surface receptors. Cell. 48:1987;549-554
66. Schraa A.J., Kok R.J., Berendsen A.D., Moorlag H.E., Bos E.J., Meijer D.K.F., de Leij L.F.M.H., Molema G. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J. Control. Release. 83:2002;241-251
67. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52:2000;237-268
68. Schraa A.J., Everts M., Kok R.J., Ásgeirsdóttir S.A., Meijer D.K.F., de Leij L.F.M.H., Molema G. El-Gewely M.R. Biotechnology Annual Review. vol. 8:2002;133-166 Elsevier, Amsterdam
69. 3 for angiogenesis. Science. 264:1994;569-571
70. Aplin A.E., Howe A., Alahari S.K., Juliano R.L. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50:1998;197-263
71. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164
72. 3 antagonist. J. Clin. Invest. 103:1999;47-54
73. Hermanson G.T., Mallia A.K., Smith P.K. Immobilized Affinity Ligand Techniques. 1992;51-136 Academic Press, San Diego
74. Snyder S.L., Sobocinski P.Z. An improved 2, 4, 6-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 64:1975;284-288
75. Hosseinkhani H., Tabata Y. In vitro gene expression by cationized derivatives of an artificial protein with repeated RGD sequences, Pronectin® J. Control. Release. 86(1):2003;169-182
76. Sato N., Kobayashi H., Saga T., Nakamoto Y., Ishimori T., Togashi K., Fujibayashi Y., Konishi J., Brechbiel M.W. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 7:2001;3606-3612
77. Fujimoto K., Inoue H., Ikada Y. Protein adsorption and platelet adhesion onto polyurethane grafted with methoxy-poly(ethylene glycol) methacrylate by plasma technique. J. Biomed. Mater. Res. 27:1993;1559-1567
78. Kishida A., Mishima K., Corretge E., Konishi H., Ikada Y. Interactions of poly(ethylene glycol)-grafted cellulose membranes with proteins and platelets. Biomaterials. 13(2):1992;113-118
79. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103:1999;1227-1230
80. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380
81. 3. Clin. Cancer Res. 6:2000;3056-3061